Skip to main content
Guizhou Xinbang Pharmaceutical Co.,Ltd. logo

Guizhou Xinbang Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 002390 ISIN · CNE100000NG5 LEI · 300300V0VT8TMAY8LY93 Shenzhen Stock Exchange Human health and social work activities
Open in API
Filings indexed 2,494 across all filing types
Latest filing 2026-05-14 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002390

About Guizhou Xinbang Pharmaceutical Co.,Ltd.

https://www.xinbang.com

Guizhou Xinbang Pharmaceutical Co.,Ltd. is an integrated healthcare enterprise focused on the research, development, production, and distribution of pharmaceutical products alongside the management of medical services. The company's pharmaceutical portfolio includes modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products, with a particular emphasis on treatments for cardiovascular, cerebrovascular, and gynecological conditions. Beyond manufacturing, the company operates a network of medical institutions, providing comprehensive healthcare services and hospital management. Its business model integrates the pharmaceutical supply chain with clinical medical care, aiming to provide holistic health solutions. Key activities involve the cultivation of medicinal herbs, the manufacturing of finished dosages, and the operation of specialized and general hospitals.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement by 贵州信邦制药股份有限公司 regarding its 2025年度权益分派 (equity distribution) implementation, specifying cash dividend per 10 shares, record date, ex-dividend date, distribution method, calculation principles, and related details for shareholders. This falls squarely under Notice of Dividend Amount (code DIV).
2026-05-14 Chinese
国浩律师（上海）事务所关于贵州信邦制药股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 72% confidence The document is a legal opinion letter issued by a law firm concerning the legality of convening and conducting the company’s 2025 Annual General Meeting (AGM). It does not contain financial results, voting results summary, proxy soliciting materials addressed to shareholders, or substantive financial statements. Instead, it is a compliance document and attestation regarding meeting procedures under Chinese corporate and securities law. There is no distinct category for a legal opinion, so it falls into the fallback category “Regulatory Filings (RNS)” for regulatory announcements, compliance documents, or attestations.
2026-05-12 Chinese
2025年度股东会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an official announcement by Guizhou Xinbang Pharmaceutical Co., Ltd. of the resolutions passed at the 2025 annual shareholders’ meeting, including detailed voting results for each proposal. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-12 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 贵州信邦制药股份有限公司 covering the fiscal year from January 1, 2025 to December 31, 2025. It includes detailed audit opinions, key audit matters such as revenue recognition and goodwill impairment, and extensive financial statement notes. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report prepared by an accounting firm, including auditor responsibilities, management responsibilities, and detailed audit procedures. It is not an annual report (10-K) because it focuses on the audit opinion and related audit information rather than the full company annual report. It is not a certification or a short announcement. Therefore, the document fits the category of Audit Report / Information (AR). FY 2025
2026-04-20 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled “内部控制审计报告” (Internal Control Audit Report) issued by an independent CPA firm (Beijing Dehao International Certified Public Accountants) on the effectiveness of the company’s internal financial controls as of December 31, 2025. It includes audit responsibilities, scope, and an audit opinion. This is a standalone audit report and not a full annual or interim financial statement, nor merely an announcement. According to the definitions, this fits “Audit Report / Information” (Code: AR). FY 2025
2026-04-20 Chinese
关于第九届董事会第十次会议决议的公告
Board/Management Information Classification · 91% confidence The document is a formal announcement (“公告”) detailing the resolutions passed at the company’s Ninth Board of Directors’ Tenth Meeting: reports reviewed, proposals approved, and items to be submitted to the shareholder meeting. It does not present financial results itself (not an earnings release or annual report) but announces board-level decisions. This falls under Board/Management Information (MANG).
2026-04-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.